Dr. Juan-Carlos Verdeja Performs Appendectomy With No Perceptible Scarring
-- Disruptive Surgical Stapler Allows Surgeons to Reach the "Five-Millimeter
Barrier" to Take Minimally-Invasive Surgery to the Next Level --
REDWOOD CITY, Calif., June 10, 2014
REDWOOD CITY, Calif., June 10, 2014 /PRNewswire/ --Cardica, Inc. (Nasdaq:
CRDC) today announced that Juan-Carlos Verdeja, M.D., F.A.C.S., completed a
laparoscopic appendectomy procedure at South Miami Hospital in Florida with
virtually no perceptible scar. Using the MicroCutter XCHANGE^® 30, the world's
first and only five-millimeter surgical stapler that articulates to 80
degrees, facilitates this surgical advance resulting in a successful removal
of the appendix and improved patient satisfaction due to minimized scarring
and recovery time.
"The recent introduction of this smaller surgical stapler with an innovative
design delivers on the promise of further reducing the impact of minimally
invasive surgery," commented Dr. Verdeja, chief of the General Surgery
Division for Baptist Health Medical Group and medical director of emergency
surgical services for Baptist Health South Florida. "The ability to use the
same, smaller trocar for all tools – camera, grasper, energy devices, and
stapler -- represents a game-changing advance in minimally-invasive surgery,
where we achieve the same surgical outcome but improve patient outcome by
using the five-millimeter stapler to further reduce the risk of infection and
pain associated with any surgical procedures."
Dr. Verdeja performed the appendectomy on a 55 year old female patient. He
deployed the MicroCutter XCHANGE 30 through the umbilicus, which leaves no
scarring, and just two 3mm incisions from the grasper and camera tools,
imperceptible to the human eye. The patient was discharged the same day, with
no complications following the procedure.
"The combined use of microlaparoscopy and the MicroCutter XCHANGE 30
represents the next level of 'downsizing' what was already considered a
minimally invasive procedure," commented Dr. Verdeja, who is also director of
laparoscopy and minimally invasive surgery at Florida International University
College of Medicine.
Cardica's MicroCutter XCHANGE 30 device received clearance from the U.S. Food
and Drug Administration for use in multiple open or minimally-invasive
surgical procedures for the transection, resection and/or creation of
anastomoses in small and large intestine, as well as the transection of the
Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to reduce operating time and facilitate
minimally-invasive and robot-assisted surgeries. Cardica's MicroCutter
XCHANGE^® 30, a cartridge-based articulating surgical stapling device with a
five-millimeter shaft diameter, is manufactured and cleared for use in a
variety of gastrointestinal procedures and appendectomies in the United
States, and is marketed for a wide range of surgical procedures in Europe.
Cardicais developing the Cardica^® MicroCutter XCHANGE^® 45, a
cartridge-based microcutter device that is being designed with an
eight-millimeter shaft to be used in a variety of procedures, including
bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter
XCHANGE 45 product requires 510(k) clearance and CE Mark and is not yet
commercially available in the U.S. or internationally. In addition, Cardica
manufactures and markets its automated anastomosis systems, the C-Port^®
Distal Anastomosis Systems and PAS-Port^® Proximal Anastomosis System for
coronary artery bypass graft (CABG) surgery, and has shipped over 50,000 units
throughout the world.
The statements in this press release regarding the anticipated benefits of
using Cardica's MicroCutter XCHANGE 30 and cartridges are "forward-looking
statements." There are a number of important factors that could cause
Cardica's results to differ materially from those indicated by these
forward-looking statements, including: that prospective customers may not
perceive the benefits of the XCHANGE 30 to be sufficient to warrant its
purchase; that prospective customers may be constrained by pricing pressures
or purchasing requirements in the hospitals and facilities in which they work,
which could prevent them from purchasing the XCHANGE 30; as well as other
risks detailed from time to time in Cardica's reports filed with the U.S.
Securities and Exchange Commission, including its Quarterly Report on Form
10-Q for the quarter endedMarch 31, 2014, under the caption "Risk Factors,"
filed on May 7, 2014. Cardica expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to read
Cardica's reports filed with the U.S. Securities and Exchange Commission,
available at www.sec.gov.
SOURCE Cardica, Inc.
Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
(650) 331-7133, email@example.com
Press spacebar to pause and continue. Press esc to stop.